High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 2: putative scenarios and timeline in case of approval, recommendations for use, implementation, and ethical considerations in France
出版年份 2022 全文链接
标题
High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 2: putative scenarios and timeline in case of approval, recommendations for use, implementation, and ethical considerations in France
作者
关键词
-
出版物
REVUE NEUROLOGIQUE
Volume -, Issue -, Pages -
出版商
Elsevier BV
发表日期
2022-11-03
DOI
10.1016/j.neurol.2022.08.002
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects
- (2022) N. Villain et al. REVUE NEUROLOGIQUE
- Comorbid neuropathological diagnoses in early versus late-onset Alzheimer’s disease
- (2021) Salvatore Spina et al. BRAIN
- Representativeness of Participants Eligible to Be Enrolled in Clinical Trials of Aducanumab for Alzheimer Disease Compared With Medicare Beneficiaries With Alzheimer Disease and Mild Cognitive Impairment
- (2021) Timothy S. Anderson et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- “Real world” eligibility for aducanumab
- (2021) Marco Canevelli et al. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
- Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group
- (2021) Bruno Dubois et al. LANCET NEUROLOGY
- Off-label use of aducanumab for cerebral amyloid angiopathy
- (2021) Steven M Greenberg et al. LANCET NEUROLOGY
- Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures
- (2021) Sebastian Palmqvist et al. NATURE MEDICINE
- Aducanumab for Alzheimer’s disease: A regulatory perspective
- (2021) Robert Nisticò et al. PHARMACOLOGICAL RESEARCH
- Influence of education level on MMSE and MoCA scores of elderly inpatients
- (2021) Yehuan Wu et al. Applied Neuropsychology-Adult
- The probabilistic model of Alzheimer disease: the amyloid hypothesis revised
- (2021) Giovanni B. Frisoni et al. NATURE REVIEWS NEUROSCIENCE
- Decisions With Patients and Families Regarding Aducanumab in Alzheimer Disease, With Recommendations for Consent
- (2021) Winston Chiong et al. NEUROLOGY
- Vessels Sing Their ARIAs: The Role of Vascular Amyloid in the Age of Aducanumab
- (2021) Lukas Sveikata et al. STROKE
- Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration
- (2020) Elisabeth H. Thijssen et al. NATURE MEDICINE
- Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders
- (2020) Sebastian Palmqvist et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- How many patients are eligible for disease-modifying treatment in Alzheimer’s disease? A French national observational study over 5 years
- (2019) Stéphane Epelbaum et al. BMJ Open
- Cerebral amyloid angiopathy and Alzheimer disease — one peptide, two pathways
- (2019) Steven M. Greenberg et al. Nature Reviews Neurology
- Estimation of lifetime risks of Alzheimer's disease dementia using biomarkers for preclinical disease
- (2018) Ron Brookmeyer et al. Alzheimers & Dementia
- Serious hemorrhages after ischemic stroke or TIA – Incidence, mortality, and predictors
- (2018) Joachim Ögren et al. PLoS One
- Vers une stratégie nationale de diagnostic des troubles cognitifs. Approche commune du Collège de médecine générale et des spécialistes des troubles neurocognitifs
- (2018) Pierre Krolak-Salmon et al. PRESSE MEDICALE
- Clinical Evaluation of Amyloid-Related Imaging Abnormalities in Bapineuzumab Phase III Studies
- (2018) H. Robert Brashear et al. JOURNAL OF ALZHEIMERS DISEASE
- Is the Folstein's Mini-Mental Test an Aphasia Test?
- (2012) Nora Silvana Vigliecca et al. Applied Neuropsychology-Adult
- Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup
- (2011) Reisa A. Sperling et al. Alzheimers & Dementia
- Amyloid-Dependent and Amyloid-Independent Stages of Alzheimer Disease
- (2011) Bradley T. Hyman ARCHIVES OF NEUROLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started